Page last updated: 2024-08-25

zoledronic acid and Adenocarcinoma, Basal Cell

zoledronic acid has been researched along with Adenocarcinoma, Basal Cell in 59 studies

Research

Studies (59)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's29 (49.15)29.6817
2010's29 (49.15)24.3611
2020's1 (1.69)2.80

Authors

AuthorsStudies
Bitzer, M; Lordick, F; Maurus, D; Sahin, U; Thuss-Patience, P; Türeci, Ö1
Imamura, Y; Matsuda, S; Sano, K; Umeda, Y; Yoshida, H; Yoshimura, H1
Bahleda, R; Escudier, B; Gueutin, V; Izzedine, H; Rouvier, P; Soria, JC; Varga, A1
Bhoopalam, N; Halabi, S; Hauke, RJ; Hussain, A; Kelly, WK; Monk, JP; Morris, M; Ryan, CJ; Saad, F; Sanford, B; Saylor, P; Small, EJ; Smith, MR; Stadler, W; Vogelzang, N1
da Silva, DP; de Almeida, FC; de Araujo, ME; Marcucci, M; Marques, MM; Moreira, MS1
Bouvet, M; Hayashi, K; Hiroshima, Y; Hoffman, RM; Kimura, H; Matsumoto, Y; Miwa, S; Sugimoto, N; Tsuchiya, H; Uehara, F; Yamamoto, M; Yamamoto, N; Yano, S; Zhang, Y1
Baine, MJ; Batra, SK; Chen, S; Gupta, S; Jain, M; Johansson, SL; Kaur, S; Lazenby, A; Lester, K; Lin, C; Rachagani, S; Smith, L; Souchek, JJ; Zheng, D1
Saad, F1
Atkinson, C; Attia, J; Christie, D; Delahunt, B; Denham, JW; Diamond, T; Duchesne, G; Gogna, NK; Joseph, D; Kenny, L; Lamb, DS; Matthews, J; Oldmeadow, C; Spry, NA; Steigler, A; Tai, KH; Turner, S1
Cappetta, A; Evangelista, L; Opocher, G; Pastorelli, D; Spano, L; Zovato, S1
Esa, A; Hara, I; Iki, M; Imanishi, M; Kajikawa, H; Komura, T; Matsuyama, H; Nagao, K; Nishioka, T; Nozawa, M; Ogawa, T; Uejima, S; Uekado, Y; Uemura, H1
Gehi, D; Rubin, CD; Tachibana, I1
Atkinson, C; Attia, J; Christie, D; Delahunt, B; Denham, JW; Duchesne, G; Egevad, L; Joseph, D; Matthews, J; Murray, JD; Spry, NA; Srigley, JR; Steigler, A1
Joensuu, TK1
Kressley, A; Saif, MW; Smith, A1
Gupta, NP; Nayyar, R; Sharma, N1
Yuasa, T1
Goto, H; Hanibuchi, M; Ikuta, K; Kakiuchi, S; Nishioka, Y; Ogino, H; Otsuka, S; Sone, S; Takahashi, T; Yamada, T; Yano, S1
Bornstein, MM; Frei, M; Iizuka, T; Reichart, PA; Schaller, B; Weimann, R1
Boudjema, K; Bouet-Toussaint, F; Cabillic, F; Catros, V; Daniel, P; de La Pintière, CT; Lavoué, V; Mönkkönen, H; Mönkkönen, J; Rioux-Leclerc, N; Toutirais, O; Turlin, B1
Hering, F; Meler, A; Rodrigues, P1
Chang, HJ; Chang, JW; Li, YY; Liu, YC; Su, SP; Tsai, MC; Wang, CH; Yeh, KY1
Fujii, N; Ito, H; Nakabayashi, M; Ryoke, K; Shomori, K; Tamura, T1
Kakehi, Y; Kato, T; Kazuki, N; Kushida, Y; Kuwata, Y; Matsuoka, Y; Taoka, T; Yamamoto, N1
Fujitaka, K; Haruta, Y; Hattori, N; Ishikawa, N; Iwamoto, H; Kanehara, M; Kohno, N; Murai, H; Nagao, S; Ohshimo, S1
Culine, S; Pouessel, D1
Belt, BA; Gillanders, WE; Goedegebuure, P; Herndon, J; Hsieh, CS; Lee, HM; Linehan, DC; Mitchem, JB; Porembka, MR1
Enomoto, Y; Fujimura, T; Fukuhara, H; Hirano, Y; Homma, Y; Igawa, Y; Ishikawa, A; Kume, H; Miyazaki, H; Nishimatsu, H; Suzuki, M1
Abdelkarim, M; Crepin, M; Di Benedetto, M; Jais, JP; Kassis, N; Lecouvey, M; Perret, GY; Vintonenko, N1
Nguyen, PL1
Atkinson, C; Christie, D; Delahunt, B; Denham, JW; Duchesne, G; Gogna, NK; Joseph, D; Kenny, L; Lamb, DS; Matthews, J; McElduff, P; Spry, NA; Tai, KH; Turner, S; Wilcox, C1
Balakumaran, A; Ciuleanu, TE; García-Sáenz, JA; Henry, DH; Hirsh, V; Jacobs, I; Kanarev, V; Krzakowski, M; Lipton, L; Manegold, C; Mehta, ND; Pereira, JR; Prabhash, K; Rodriguez, G; Scagliotti, GV; Siena, S; Solal-Celigny, P; Wang, H; Woll, PJ1
Dohdoh, M; Endo, Y; Kuroishi, T; Nagai, Y; Ohki, A; Oizumi, T; Sugawara, S; Tanaka, Y1
Gomez-Veiga, F; Martinez-Breijo, S; Morote, J; Planas, J; Ponce-Reixa, J1
Datta, HK; Hanusch, B; Tuck, SP; Walker, J1
Davies, M; Gates, J; Jo, M; Lee, YP; Lieberman, JR; Schwarz, EM; Wu, J; Zhang, X1
Chen, B; Chin, JL; Gleason, DM; Goas, JA; Lacombe, L; Murray, R; Saad, F; Tchekmedyian, S; Venner, P; Vinholes, JJ1
Gleason, D; Gordon, D; Kowalski, MO; Lipton, A; Reitsma, D; Rosen, L; Saad, F; Seaman, J; Small, E; Smith, M1
Altundag, K; Altundag, O; Gunduz, M; Morandi, P2
Antoniou, N; Bamias, A; Bozas, G; Deliveliotis, C; Dimopoulos, MA; Efstathiou, E; Kastritis, E; Kostakopoulos, A; Papadimitriou, C; Skarlos, D1
Brahmbhatt, V; Patel, K; Ramu, V1
Altun, B; Altundag, K; Elkiran, T; Gullu, I; Kurt, M; Onal, IK1
Hellie, CM; Olson, KB; Pienta, KJ1
Cormio, G; Cuccovillo, A; Fattizzi, N; Loizzi, V; Selvaggi, L1
Katsouda, E; Mystakidou, K; Parpa, E; Vlahos, L1
Bishop, PA; Hay, KD1
Beer, TM; Demers, LM; Huo, D; Lacerna, LV; Ryan, CW1
Doyle-Lindrud, S1
Abbruzzese, A; Baldi, A; Bertieri, R; Budillon, A; Caraglia, M; D'Alessandro, AM; Leonetti, C; Marra, M; Meo, G; Santini, D; Tonini, G; Zupi, G1
Kenna, T; Mattarollo, SR; Nicol, AJ; Nieda, M1
Altieri, V; Autorino, R; Cancello, G; D'Armiento, M; De Laurentiis, M; De Placido, S; Di Lorenzo, G; Figg, WD; Imbimbo, C; Longo, N; Mirone, V; Perdonà, S; Tortora, G1
Duivenvoorden, WC; Kalina, M; Seidlitz, E; Singh, G; Vukmirović-Popović, S1
Afonso, Y; Bruna, P; Hering, FO; Meller, A; Rodrigues, P1
Bylow, K; Demers, LM; Henderson, TO; Huo, D; Ryan, CW; Stadler, WM; Vogelzang, NJ1
Bellomi, M; Bruschini, R; Cossu Rocca, M; Goldhirsch, A; Nole, F; Preda, L; Sanna, G; Verri, E1
Aguilera Tubet, C; Ballestero Diego, R; Roca Edreira, A; Villanueva Peña, A; Zubillaga Guerrero, S1
Arlen, PM; Dahut, WL; Gulley, JL; Wu, S1
Fernandez, SA; Martin, CK; Nadella, MV; Pinzone, JJ; Rosol, TJ; Thudi, NK; Werbeck, JL1

Reviews

5 review(s) available for zoledronic acid and Adenocarcinoma, Basal Cell

ArticleYear
Advances in prevention and treatment of bone metastases in prostate cancer. Role of RANK/RANKL inhibition.
    Actas urologicas espanolas, 2013, Volume: 37, Issue:5

    Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Clinical Trials, Phase III as Topic; Denosumab; Diphosphonates; Double-Blind Method; Forecasting; Fractures, Spontaneous; Humans; Imidazoles; Male; Models, Biological; Molecular Targeted Therapy; Multicenter Studies as Topic; Neoplasm Proteins; Practice Guidelines as Topic; Prostatic Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Zoledronic Acid

2013
The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate.
    Cancer investigation, 2002, Volume: 20 Suppl 2

    Topics: Adenocarcinoma; Biomarkers; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Double-Blind Method; Female; Humans; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Multiple Myeloma; Osteoblasts; Osteoclasts; Osteolysis; Osteoporosis; Pain; Pamidronate; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Safety; Zoledronic Acid

2002
Osteonecrosis of jaw in patient with hormone-refractory prostate cancer treated with zoledronic acid.
    Urology, 2005, Volume: 66, Issue:3

    Topics: Adenocarcinoma; Androgen Antagonists; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Male; Middle Aged; Osteonecrosis; Prostatic Neoplasms; Treatment Failure; Zoledronic Acid

2005
Two cases of endometrial cancer diagnosis associated with bone metastasis.
    Gynecologic and obstetric investigation, 2006, Volume: 61, Issue:1

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Cervical Vertebrae; Cyclophosphamide; Diphosphonates; Doxorubicin; Endometrial Neoplasms; Fatal Outcome; Female; Humans; Imidazoles; Middle Aged; Platinum; Spinal Neoplasms; Tibia; Zoledronic Acid

2006
Implications of androgen-deprivation therapy in patients with prostate cancer: A case study.
    Clinical journal of oncology nursing, 2006, Volume: 10, Issue:5

    Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Combined Modality Therapy; Diphosphonates; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Jaw Diseases; Leuprolide; Male; Orchiectomy; Osteonecrosis; Osteoporosis; Prostate-Specific Antigen; Prostatic Neoplasms; Radiotherapy, Conformal; Risk Factors; Tomography, X-Ray Computed; Zoledronic Acid

2006

Trials

14 trial(s) available for zoledronic acid and Adenocarcinoma, Basal Cell

ArticleYear
Immunological effects and activity of multiple doses of zolbetuximab in combination with zoledronic acid and interleukin-2 in a phase 1 study in patients with advanced gastric and gastroesophageal junction cancer.
    Journal of cancer research and clinical oncology, 2023, Volume: 149, Issue:9

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Claudins; Esophagogastric Junction; Humans; Interleukin-2; Stomach Neoplasms; Zoledronic Acid

2023
Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance).
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Apr-10, Volume: 32, Issue:11

    Topics: Adenocarcinoma; Aged; Androgen Antagonists; Bone Density Conservation Agents; Bone Neoplasms; Diagnostic Imaging; Diphosphonates; Disease Progression; Humans; Imidazoles; Male; Orchiectomy; Prostatic Neoplasms; Treatment Outcome; Zoledronic Acid

2014
Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial
    The Lancet. Oncology, 2014, Volume: 15, Issue:10

    Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Brachytherapy; Combined Modality Therapy; Diphosphonates; Disease-Free Survival; Drug Administration Schedule; Follow-Up Studies; Humans; Imidazoles; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Treatment Outcome; Zoledronic Acid

2014
Significance of baseline bone markers on disease progression and survival in hormone-sensitive prostate cancer with bone metastasis.
    World journal of urology, 2015, Volume: 33, Issue:9

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Alkaline Phosphatase; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Bone Neoplasms; Diphosphonates; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Therapy, Combination; Follow-Up Studies; Goserelin; Humans; Imidazoles; Japan; Male; Middle Aged; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Risk Factors; Survival Rate; Time Factors; Tosyl Compounds; Zoledronic Acid

2015
Validation of International Society of Urological Pathology (ISUP) grading for prostatic adenocarcinoma in thin core biopsies using TROG 03.04 'RADAR' trial clinical data.
    Pathology, 2015, Volume: 47, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Androgen Antagonists; Antineoplastic Agents; Biopsy, Large-Core Needle; Chemoradiotherapy; Consensus Development Conferences as Topic; Diphosphonates; Humans; Imidazoles; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Grading; Pathology, Surgical; Proportional Hazards Models; Prostatic Neoplasms; Societies, Medical; Urology; Zoledronic Acid

2015
Docetaxel-based chemotherapy with zoledronic acid and prednisone in hormone refractory prostate cancer: factors predicting response and survival.
    International journal of urology : official journal of the Japanese Urological Association, 2009, Volume: 16, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Diphosphonates; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Humans; Imidazoles; Karnofsky Performance Status; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prednisone; Prognosis; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Treatment Outcome; Zoledronic Acid

2009
Titration of dosage for the protective effect of zoledronic acid on bone loss in patients submitted to androgen deprivation therapy due to prostate cancer: a prospective open-label study.
    Urologia internationalis, 2010, Volume: 85, Issue:2

    Topics: Absorptiometry, Photon; Adenocarcinoma; Aged; Androgen Antagonists; Bone Density; Bone Density Conservation Agents; Brazil; Chemotherapy, Adjuvant; Diphosphonates; Drug Administration Schedule; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Infusions, Intravenous; Lumbar Vertebrae; Male; Neoplasm Recurrence, Local; Osteoporosis; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Time Factors; Treatment Outcome; Zoledronic Acid

2010
Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial.
    The Lancet. Oncology, 2012, Volume: 13, Issue:12

    Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Brachytherapy; Diphosphonates; Humans; Imidazoles; Leuprolide; Male; Middle Aged; Neoadjuvant Therapy; Prostatic Neoplasms; Quality of Life; Radiotherapy Dosage; Zoledronic Acid

2012
Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2012, Volume: 7, Issue:12

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Denosumab; Diphosphonates; Double-Blind Method; Female; Follow-Up Studies; Humans; Imidazoles; International Agencies; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; RANK Ligand; Small Cell Lung Carcinoma; Survival Rate; Young Adult; Zoledronic Acid

2012
A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.
    Journal of the National Cancer Institute, 2002, Oct-02, Volume: 94, Issue:19

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Biomarkers; Bone Density; Bone Neoplasms; Bone Resorption; Diphosphonates; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Imidazoles; Infusions, Intravenous; Male; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Quality of Life; Treatment Outcome; Zoledronic Acid

2002
Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer.
    The Journal of urology, 2006, Volume: 176, Issue:3

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Diphosphonates; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Male; Middle Aged; Orchiectomy; Prostatic Neoplasms; Time Factors; Zoledronic Acid

2006
Docetaxel, vinorelbine, and zoledronic acid as first-line treatment in patients with hormone refractory prostate cancer: a phase II study.
    European urology, 2007, Volume: 52, Issue:4

    Topics: Adenocarcinoma; Aged; Biomarkers, Tumor; Bone Neoplasms; Diphosphonates; Docetaxel; Humans; Imidazoles; Male; Middle Aged; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Survivors; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine; Zoledronic Acid

2007
Comparative study of the protective effect of different intravenous bisphosphonates on the decrease in bone mineral density in patients submitted to radical prostatectomy undergoing androgen deprivation therapy. A prospective open-label controlled study.
    International journal of urology : official journal of the Japanese Urological Association, 2007, Volume: 14, Issue:4

    Topics: Adenocarcinoma; Aged; Androgen Antagonists; Bone Density; Bone Density Conservation Agents; Clodronic Acid; Diphosphonates; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Orchiectomy; Osteoporosis; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Zoledronic Acid

2007
Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid.
    BJU international, 2007, Volume: 100, Issue:1

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodeling; Diphosphonates; Double-Blind Method; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Male; Middle Aged; Orchiectomy; Osteoporosis; Prostatic Neoplasms; Retrospective Studies; Treatment Outcome; Zoledronic Acid

2007

Other Studies

40 other study(ies) available for zoledronic acid and Adenocarcinoma, Basal Cell

ArticleYear
Mandibular metastasis as the first clinical indication of occult lung adenocarcinoma with multiple metastases: A case report.
    Medicine, 2018, Volume: 97, Issue:15

    Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged, 80 and over; Antineoplastic Agents; Biopsy; Bone Density Conservation Agents; Diagnosis, Differential; Diphosphonates; Female; Gefitinib; Humans; Imidazoles; Immunohistochemistry; Lung; Lung Neoplasms; Mandible; Mandibular Neoplasms; Neoplasm Grading; Neoplasm Staging; Quinazolines; Thyroid Neoplasms; Treatment Outcome; Zoledronic Acid

2018
Acute tubular necrosis associated with mTOR inhibitor therapy: a real entity biopsy-proven.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:9

    Topics: Acute Kidney Injury; Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Carcinoma, Renal Cell; Cisplatin; Cyclophosphamide; Diphosphonates; Doxorubicin; Female; Glutamates; Guanine; Humans; Imidazoles; Indoles; Interferons; Kidney Tubules; Lung Neoplasms; Lymphoma, B-Cell; Male; Mediastinal Neoplasms; Middle Aged; Necrosis; Nephrectomy; Pemetrexed; Prednisone; Pyrroles; Sunitinib; TOR Serine-Threonine Kinases; Vincristine; Zoledronic Acid

2013
New uses for rehabilitation protocol for oral sinus communications in ARONJ patients.
    Journal of prosthodontics : official journal of the American College of Prosthodontists, 2014, Volume: 23, Issue:8

    Topics: Adenocarcinoma; Aged; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Clinical Protocols; Dental Prosthesis Design; Denture Design; Denture, Complete, Upper; Diphosphonates; Follow-Up Studies; Humans; Imidazoles; Jaw, Edentulous; Male; Maxilla; Neoadjuvant Therapy; Oroantral Fistula; Palatal Obturators; Patient Care Planning; Prostatic Neoplasms; Zoledronic Acid

2014
Fluorescence-guided surgery of prostate cancer bone metastasis.
    The Journal of surgical research, 2014, Volume: 192, Issue:1

    Topics: Adenocarcinoma; Animals; Bone Density Conservation Agents; Bone Neoplasms; Cell Line, Tumor; Diphosphonates; Disease Models, Animal; Disease-Free Survival; Green Fluorescent Proteins; Humans; Imidazoles; Luminescent Proteins; Lymphatic Metastasis; Male; Mice, Nude; Neoplasm Recurrence, Local; Neoplasm, Residual; Optical Imaging; Prostatic Neoplasms; Red Fluorescent Protein; Zoledronic Acid

2014
Unbiased analysis of pancreatic cancer radiation resistance reveals cholesterol biosynthesis as a novel target for radiosensitisation.
    British journal of cancer, 2014, Sep-09, Volume: 111, Issue:6

    Topics: Adenocarcinoma; Animals; Cell Line, Tumor; Cholesterol; Diphosphonates; DNA, Complementary; Gene Expression Profiling; Gene Knockdown Techniques; Geranyltranstransferase; Humans; Imidazoles; Immunohistochemistry; Mice; Mice, Inbred C57BL; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Radiation Tolerance; Radiation-Sensitizing Agents; Zoledronic Acid

2014
Role of bisphosphonates in non-metastatic prostate cancer.
    The Lancet. Oncology, 2014, Volume: 15, Issue:10

    Topics: Adenocarcinoma; Androgen Antagonists; Brachytherapy; Diphosphonates; Humans; Imidazoles; Male; Neoplasm Recurrence, Local; Prostatic Neoplasms; Zoledronic Acid

2014
Impressive response to denosumab in a patient with bone metastatic adenocarcinoma of the stomach after 2 years of zoledronic acid.
    Anti-cancer drugs, 2015, Volume: 26, Issue:2

    Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Female; Fluorodeoxyglucose F18; Humans; Imidazoles; Middle Aged; Positron-Emission Tomography; Stomach Neoplasms; Treatment Outcome; Zoledronic Acid

2015
Treatment of Hypertrophic Osteoarthropathy With Underlying Pulmonary Adenocarcinoma Using Zoledronic Acid.
    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2015, Volume: 21, Issue:6

    Topics: Adenocarcinoma; Adenocarcinoma of Lung; Analgesics, Opioid; Bone Density Conservation Agents; Diphosphonates; Glucocorticoids; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Osteoarthropathy, Secondary Hypertrophic; Pain Management; Pain Measurement; Pneumonectomy; Treatment Outcome; Zoledronic Acid

2015
Renal toxicity following zoledronic acid reversed with ibandronate in a prostate cancer patient with bone metastases.
    Urologia internationalis, 2008, Volume: 80, Issue:4

    Topics: Acute Kidney Injury; Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Bone Neoplasms; Creatinine; Diphosphonates; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Male; Palliative Care; Prostate-Specific Antigen; Prostatic Neoplasms; Retreatment; Risk Assessment; Treatment Outcome; Zoledronic Acid

2008
Oral osteonecrosis associated with the use of zoledronic acid: first case of a patient with advanced pancreatic cancer and bone metastases.
    JOP : Journal of the pancreas, 2009, Mar-09, Volume: 10, Issue:2

    Topics: Adenocarcinoma; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Male; Middle Aged; Neoplasm Staging; Osteonecrosis; Pancreatic Neoplasms; Zoledronic Acid

2009
Editorial Comment to docetaxel-based combination chemotherapy with zoledronic acid and prednisone in hormone refractory prostate cancer: Factors predicting response and survival.
    International journal of urology : official journal of the Japanese Urological Association, 2009, Volume: 16, Issue:9

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Diphosphonates; Docetaxel; Drug Administration Schedule; Humans; Imidazoles; Male; Neoplasms, Hormone-Dependent; Prednisone; Prostatic Neoplasms; Taxoids; Treatment Outcome; Zoledronic Acid

2009
A bone metastasis model with osteolytic and osteoblastic properties of human lung cancer ACC-LC-319/bone2 in natural killer cell-depleted severe combined immunodeficient mice.
    Oncology research, 2009, Volume: 17, Issue:11-12

    Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Bone Neoplasms; Cell Line, Tumor; Diphosphonates; Disease Models, Animal; Endothelin-1; Humans; Imidazoles; Killer Cells, Natural; Lung Neoplasms; Male; Mice; Mice, Inbred ICR; Mice, SCID; Osteoblasts; Osteolysis; Vascular Endothelial Growth Factor A; Zoledronic Acid

2009
Bisphosphonate-related osteonecrosis of the jaw combined with jaw metastasis of prostate adenocarcinoma: report of a case.
    Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2010, Volume: 68, Issue:4

    Topics: Adenocarcinoma; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Male; Mandibular Diseases; Mandibular Neoplasms; Middle Aged; Osteonecrosis; Prostatic Neoplasms; Zoledronic Acid

2010
Aminobisphosphonate-pretreated dendritic cells trigger successful Vgamma9Vdelta2 T cell amplification for immunotherapy in advanced cancer patients.
    Cancer immunology, immunotherapy : CII, 2010, Volume: 59, Issue:11

    Topics: Adenocarcinoma; Aged; Blotting, Western; Bone Density Conservation Agents; Carcinoma, Hepatocellular; Cell Differentiation; Cell Proliferation; Coculture Techniques; Colorectal Neoplasms; Cytotoxicity, Immunologic; Dendritic Cells; Diphosphates; Diphosphonates; Female; Flow Cytometry; Hemiterpenes; Humans; Imidazoles; Immunotherapy, Adoptive; Liver Neoplasms; Male; Middle Aged; Organophosphorus Compounds; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocyte Subsets; Zoledronic Acid

2010
Zoledronic acid induces cell-cycle prolongation in murine lung cancer cells by perturbing cyclin and Ras expression.
    Anti-cancer drugs, 2011, Volume: 22, Issue:1

    Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Cyclin-Dependent Kinases; Cyclins; Diphosphonates; Diterpenes; Down-Regulation; E2F Transcription Factors; Imidazoles; Lung Neoplasms; Mevalonic Acid; Mice; Mice, Inbred BALB C; Phosphorylation; Protein Transport; ras Proteins; Retinoblastoma Protein; Zoledronic Acid

2011
Zoledronic acid, a third-generation bisphosphonate, inhibits cellular growth and induces apoptosis in oral carcinoma cell lines.
    Oncology reports, 2011, Volume: 25, Issue:4

    Topics: Adenocarcinoma; Apoptosis; Blotting, Western; Bone Density Conservation Agents; Carcinoma, Squamous Cell; Caspases; Cell Cycle; Cell Proliferation; Diphosphonates; Flow Cytometry; Humans; Imidazoles; Immunoenzyme Techniques; Mouth Neoplasms; Salivary Gland Neoplasms; Tumor Cells, Cultured; Zoledronic Acid

2011
[Disseminated carcinomatosis of the bone marrow in two patients with prostate cancer].
    Nihon Hinyokika Gakkai zasshi. The japanese journal of urology, 2011, Volume: 102, Issue:1

    Topics: Adenocarcinoma; Aged; Androgen Antagonists; Anilides; Antineoplastic Agents; Bone Marrow Neoplasms; Carcinoma; Diphosphonates; Disseminated Intravascular Coagulation; Drug Therapy, Combination; Fatal Outcome; Humans; Imidazoles; Leuprolide; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Tosyl Compounds; Treatment Outcome; Zoledronic Acid

2011
Regression of a primary pulmonary adenocarcinoma after zoledronic acid monotherapy.
    Hiroshima journal of medical sciences, 2011, Volume: 60, Issue:1

    Topics: Adenocarcinoma; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Lung Neoplasms; Middle Aged; Neoplasm Regression, Spontaneous; Zoledronic Acid

2011
Complete clinical and biological response to zoledronic acid in castrate-resistant prostate cancer metastatic to bone.
    Anti-cancer drugs, 2012, Volume: 23, Issue:1

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Male; Prostatectomy; Prostatic Neoplasms; Zoledronic Acid

2012
Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth.
    Cancer immunology, immunotherapy : CII, 2012, Volume: 61, Issue:9

    Topics: Adenocarcinoma; Animals; Bone Marrow Cells; Cell Differentiation; Diphosphonates; Disease Models, Animal; Humans; Imidazoles; Mice; Mice, Inbred C57BL; Myeloid Cells; Pancreatic Neoplasms; Tumor Microenvironment; Up-Regulation; Zoledronic Acid

2012
Leukopenia as a risk factor for osteonecrosis of the jaw in metastatic prostate cancer treated using zoledronic acid and docetaxel.
    BJU international, 2012, Volume: 110, Issue:11 Pt B

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Bone Density Conservation Agents; Diphosphonates; Docetaxel; Drug Therapy, Combination; Humans; Imidazoles; Incidence; Japan; Jaw Neoplasms; Leukopenia; Male; Middle Aged; Osteonecrosis; Prognosis; Prostatic Neoplasms; Retrospective Studies; Risk Factors; Taxoids; Zoledronic Acid

2012
Transcriptome analysis and in vivo activity of fluvastatin versus zoledronic acid in a murine breast cancer metastasis model.
    Molecular pharmacology, 2012, Volume: 82, Issue:3

    Topics: Adenocarcinoma; Animals; Breast Neoplasms; Cell Line, Tumor; Diphosphonates; Disease Models, Animal; Disease Progression; Fatty Acids, Monounsaturated; Female; Fluvastatin; Gene Expression; Gene Expression Profiling; Humans; Imidazoles; Indoles; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Neoplasm Metastasis; Transcriptome; Zoledronic Acid

2012
Harms versus benefits with duration of androgen suppression.
    The Lancet. Oncology, 2012, Volume: 13, Issue:12

    Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Brachytherapy; Diphosphonates; Humans; Imidazoles; Leuprolide; Male; Prostatic Neoplasms; Quality of Life; Zoledronic Acid

2012
In vitro cytotoxicity of zoledronate (nitrogen-containing bisphosphonate: NBP) and/or etidronate (non-NBP) in tumour cells and periodontal cells.
    Archives of oral biology, 2013, Volume: 58, Issue:6

    Topics: Adenocarcinoma; Annexin A5; Apoptosis; Bone Density Conservation Agents; Carcinoma, Squamous Cell; Cell Culture Techniques; Cell Line, Tumor; Cell Survival; Cells, Cultured; Coloring Agents; Dental Cementum; Diphosphonates; Endothelial Cells; Endothelium, Vascular; Etidronic Acid; Fibroblasts; Fluorescein-5-isothiocyanate; Fluorescent Dyes; Gingiva; Humans; Imidazoles; Leukemia, Monocytic, Acute; Mesenchymal Stem Cells; Periodontal Ligament; Propidium; Tetrazolium Salts; Umbilical Veins; Zoledronic Acid

2013
Prostate cancer and osteoporosis.
    Current osteoporosis reports, 2013, Volume: 11, Issue:1

    Topics: Adenocarcinoma; Androgen Antagonists; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Humans; Imidazoles; Male; Osteoporosis; Prostatic Neoplasms; Risk Factors; Zoledronic Acid

2013
Use of zoledronate to treat osteoblastic versus osteolytic lesions in a severe-combined-immunodeficient mouse model.
    Cancer research, 2002, Oct-01, Volume: 62, Issue:19

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Hindlimb; Humans; Imidazoles; Male; Mice; Mice, SCID; Osteoblasts; Osteoclasts; Prostatic Neoplasms; Radiography; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; Zoledronic Acid

2002
High-dose calcitriol, zoledronate, and dexamethasone for the treatment of progressive prostate carcinoma.
    Cancer, 2004, Sep-01, Volume: 101, Issue:5

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Calcitriol; Dexamethasone; Diphosphonates; Disease Progression; Humans; Imidazoles; Male; Prostatic Neoplasms; Treatment Outcome; Zoledronic Acid

2004
Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.
    Urology, 2005, Volume: 65, Issue:1

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Alopecia; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Combined Modality Therapy; Diphosphonates; Disease Progression; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Estramustine; Humans; Imidazoles; Life Tables; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Proteins; Neutropenia; Orchiectomy; Pain; Palliative Care; Prostate-Specific Antigen; Prostatic Neoplasms; Radiotherapy, High-Energy; Remission Induction; Survival Analysis; Taxoids; Treatment Outcome; Zoledronic Acid

2005
Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer.
    Urology, 2005, Volume: 65, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Diphosphonates; Humans; Imatinib Mesylate; Imidazoles; Male; Neoplasm Proteins; Palliative Care; Piperazines; Prostatic Neoplasms; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Treatment Failure; Zoledronic Acid

2005
Zoledronic acid-induced severe hypocalcaemia in a prostate cancer patient with extensive osteoblastic bone metastases.
    Tennessee medicine : journal of the Tennessee Medical Association, 2005, Volume: 98, Issue:2

    Topics: Adenocarcinoma; Aged; Bone Neoplasms; Bone Resorption; Diphosphonates; Humans; Hypocalcemia; Imidazoles; Male; Pain; Prostatic Neoplasms; Zoledronic Acid

2005
Acute tumor lysis syndrome triggered by zoledronic Acid in a patient with metastatic lung adenocarcinoma.
    Medical oncology (Northwood, London, England), 2005, Volume: 22, Issue:2

    Topics: Acute Disease; Adenocarcinoma; Diphosphonates; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Treatment Outcome; Tumor Lysis Syndrome; Zoledronic Acid

2005
Prostate cancer presenting with normal serum PSA levels and boney metastases treated with zoledronic acid.
    Journal of pain & palliative care pharmacotherapy, 2005, Volume: 19, Issue:3

    Topics: Adenocarcinoma; Aged; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Male; Predictive Value of Tests; Prostate-Specific Antigen; Prostatic Neoplasms; Zoledronic Acid

2005
Association of osteonecrosis of the jaws and bisphosphonate pharmacotherapy: dental implications.
    The New Zealand dental journal, 2006, Volume: 102, Issue:1

    Topics: Adenocarcinoma; Aged, 80 and over; Bone Density Conservation Agents; Carcinoma; Diabetes Mellitus, Type 2; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Male; Mandibular Diseases; Maxillary Diseases; Middle Aged; Multiple Myeloma; Osteonecrosis; Pamidronate; Patient Care Planning; Tooth Extraction; Zoledronic Acid

2006
R115777 (Zarnestra)/Zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation.
    Journal of cellular physiology, 2007, Volume: 211, Issue:2

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; bcl-Associated Death Protein; Caspases; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Humans; Imidazoles; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Quinolones; ras Proteins; Signal Transduction; Time Factors; Xenograft Model Antitumor Assays; Zoledronic Acid

2007
Chemotherapy and zoledronate sensitize solid tumour cells to Vgamma9Vdelta2 T cell cytotoxicity.
    Cancer immunology, immunotherapy : CII, 2007, Volume: 56, Issue:8

    Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Burkitt Lymphoma; Carcinoma; Cell Line, Tumor; Cisplatin; Colorectal Neoplasms; Concanavalin A; Cytotoxicity, Immunologic; Diphosphonates; Doxorubicin; Drug Screening Assays, Antitumor; Drug Synergism; Etoposide; Female; Genes, T-Cell Receptor delta; Genes, T-Cell Receptor gamma; Humans; Imidazoles; Interferon-gamma; Lovastatin; Lung Neoplasms; Male; Membrane Glycoproteins; Neoplasms; Perforin; Pore Forming Cytotoxic Proteins; Prostatic Neoplasms; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocyte Subsets; Urinary Bladder Neoplasms; Vincristine; Zoledronic Acid

2007
Effect of zoledronic acid on the doxycycline-induced decrease in tumour burden in a bone metastasis model of human breast cancer.
    British journal of cancer, 2007, May-21, Volume: 96, Issue:10

    Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Disease Models, Animal; Doxycycline; Drug Synergism; Female; Humans; Imidazoles; Mice; Mice, Nude; Tumor Burden; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; Zoledronic Acid

2007
The role of surgery in jaw bone necrosis associated with long-term use of bisphosphonates.
    Acta oncologica (Stockholm, Sweden), 2008, Volume: 47, Issue:3

    Topics: Adenocarcinoma; Bone Neoplasms; Bone Plates; Bone Screws; Breast Neoplasms; Cutaneous Fistula; Diphosphonates; Female; Humans; Imidazoles; Male; Mandible; Mandibular Diseases; Middle Aged; Necrosis; Oral Fistula; Osteolysis; Osteomyelitis; Pamidronate; Prostatic Neoplasms; Recurrence; Tomography, X-Ray Computed; Zoledronic Acid

2008
[Mediastinal lymph nodes during the course of a metastatic prostate cancer].
    Actas urologicas espanolas, 2007, Volume: 31, Issue:6

    Topics: Adenocarcinoma; Androgen Antagonists; Androgens; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyproterone; Diphosphonates; Estramustine; Fatal Outcome; Flutamide; Humans; Imidazoles; Ketoconazole; Lung Neoplasms; Lymphatic Metastasis; Male; Mediastinum; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Radionuclide Imaging; Skin Neoplasms; Triptorelin Pamoate; Zoledronic Acid

2007
Persistent hypocalcemia induced by zoledronic acid in a patient with androgen-independent prostate cancer and extensive bone metastases.
    Clinical genitourinary cancer, 2007, Volume: 5, Issue:6

    Topics: Adenocarcinoma; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Diphosphonates; Humans; Hypocalcemia; Imidazoles; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Zoledronic Acid

2007
Zoledronic acid decreased osteolysis but not bone metastasis in a nude mouse model of canine prostate cancer with mixed bone lesions.
    The Prostate, 2008, Jul-01, Volume: 68, Issue:10

    Topics: Adenocarcinoma; Animals; Bone Density Conservation Agents; Bone Neoplasms; Cell Line, Transformed; Diphosphonates; Disease Models, Animal; Dogs; Imidazoles; Incidence; Luminescent Proteins; Male; Mice; Mice, Nude; Osteoclasts; Osteolysis; Prostatic Neoplasms; Radiography; Zoledronic Acid

2008